Wednesday, 16 Jan 2019

You are here

Fish Oil Fails in Dry Eye Trial

Many topical and OTC products are recommended when treating chronic dry eyes, including omega-3 fatty acids (fish oil or n−3 fatty acids) to relieve symptoms; the NEJM reports that the DREAM trial shows no clinical benefit of n−3 fatty acids for 12 months when compared to placebo.

Patients (n=535) with moderate-to-severe dry eye disease were randomized (2:1) to receive daily oral dose of 3000 mg of fish-derived n−3 eicosapentaenoic and docosahexaenoic acids or an olive oil placebo (placebo group). The primary outcome was the mean change from baseline in the score on the Ocular Surface Disease Index (OSDI; scores on a 0 to 100 scale.

At 12 months, the mean change in the OSDI (dry eye) score was not significantly different between the active supplement group and the placebo group (−13.9 points and −12.5 points, respectively (P=0.21). Likewise there were no differences in secondary outcomes (conjunctival staining score, corneal staining score, tear break-up time or Schirmer’s test).

Rates of adverse events were similar in the two trial groups.

Patients with chronic dry eys treated with n-3 fatty acids failed to achieve significantly better outcomes than those on placebo. (DREAM ClinicalTrials.gov number, NCT02128763.)

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Price of Drug Promotion Skyrockets

JAMA reports that health care advertising costs in the U.S. have almost doubled over the past two decades, surging from $17.7 billion in 1997 to at least $29.9 billion in 2016. (Citation source: https://buff.ly/2Rk8a9Q)

2018 Rheumatology Year In Review

This annual appraisal of hallmark moments, news and research articles from 2018 are gleaned from that published in RheumNow during the last year and filtered by other news sources and literature review.  The top 10 list herein is rooted in what rheumatologists should know and what will likely change their standards and practice in the future, if not 2019. 

Best of 2018: Advance Practice Clinicians Proliferating in Specialty Practices

An analysis of SK&A outpatient provider files, covering 90% of physician practices in the United States, shows that between 2008 to 2016, there was a 22% increase in the employment of advanced practice clinicians (APCs) by specialty practices.  By 2016, 28% of all specialty practices employed APCs.

Best of 2018: Patients May Not Fill Your Prescription

A new study linking administrative claims and electronic health records (EHRs) shows that nearly 40% of patients fill and take newly prescribed methotrexate (MTX), tofacitinib or biologics. 

Kan et al set out to estimate the extent and predictors of primary nonadherence in rheumatoid arthritis (RA) patients who received new prescriptions for methotrexate, biologics or tofacitinib.

Rising Physician Exclusion from Medicare and Medicaid

JAMA Network Open has published that an increasing number of physicians are being excluded from Medicare and other forms of public insurance. 

Overall the authors found that the number of physicians excluded from Medicare, Medicaid, and other state public insurance programs increased on average by 20% per year between 2007 and 2017.